The Latest Breaking News from ICMR

Dr. Roy advises taking precautions to reduce risk of Nipah virus infections. Washing hands, avoiding contact with animals, and limiting contact with infected people are key steps. ICMR is working to contain Nipah in restricted regions and raise awareness.

ICMR-NITM inaugurated a nat'l-level training prog. for young professionals on designing & conducting clinical trials in Belagavi. Aparna Mukherjee promised ICMR support for good clinical trials. C. Padma Priyadarshini said clinical trials of traditional healing practices is needed. Subarna Roy said ICMR-NITM is pioneering research & clinical trials in Integrative…

An ICMR study has found that at least one dose of vaccine prior to COVID-19 infection provided 60% protection against post-discharge mortality

ICMR Bioethics Unit has proposed a consensus policy statement to introduce Controlled Human Infection Studies (CHIS) in India, which involves exposing healthy volunteers to pathogens in a controlled environment. The document addresses ethical concerns and outlines potential benefits, such as accelerating the development of novel medical interventions, improved pandemic preparedness,…

Health Ministry says sudden deaths of youth after COVID-19 unconfirmed and ICMR conducting 3 studies. Health Department is providing support to States/UTs

The Advanced Mycology Diagnostic and Research Centre (AMDRC) of the Indian Council of Medical Research (ICMR) was inaugurated at St. John’s Medical College and Hospital on Tuesday.

The Director-General of Indian Council of Medical Research (ICMR), Rajiv Bahl, on Saturday said that the Centre was keen on reducing the country’s dependence on import and provide high quality, affordable assistive technologies to every person in need

Age and co-morbidity are definite factors that affect the outcome of contracting COVID-19, Rajiv Bahl, Director General of the Indian Council of Medical Research (ICMR), has said.

Moving closer to being able to develop the country’s first vaccine against dengue, drug-makers Serum Institute of India and Panacea Biotec have applied to the Indian Council of Medical Research’s (ICMR) call for Expression of Interest’ for collaborative Phase-III clinical trials for indigenous manufacturers.